GTJA Leads $39M Round In Chinese Antibody Drug Developer Mabworks

This Data Is Locked!

This area is available only to Subscribers.

Shenzhen GTJA Investment Group, a Shenzhen-based Chinese private equity firm focused on the healthcare industry, has led a RMB270 million (US$39 million) series B round... [DATA LOCKED]

UNLOCK DATA

Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals

Access Thousands of Data Points to Monitor Chinese Private Equity Deal Movement and Relationships

Already Have an Account?